```html

Zollinger‑Ellison Syndrome (Sporadic)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrin‑secreting neuroendocrine tumors (gastrinomas) develop in the pancreas or duodenum. These tumors produce excess gastrin, a hormone that drives the stomach to produce large amounts of acid. The resulting hyperacidity can lead to severe peptic ulcers, diarrhea, and malabsorption.

When the gastrinomas arise sporadically—meaning they are not associated with the inherited condition Multiple Endocrine Neoplasia type 1 (MEN‑1)—the syndrome is termed “sporadic ZES.” Sporadic cases account for roughly 70–80 % of all ZES patients.<sup>1</sup>

Both men and women can be affected, with a slight male predominance (≈55 %). The average age at diagnosis is 45–55 years, but cases have been reported from childhood through late adulthood.<sup>2</sup>

Because the disease is rare, its exact prevalence is uncertain. Epidemiologic studies estimate an incidence of 0.5–2 cases per million people per year, translating to roughly 2,000–4,000 new cases in the United States annually.<sup>3</sup>

Symptoms

Excess gastric acid production can affect the gastrointestinal (GI) tract in many ways. The symptom pattern may be intermittent, severe, or progressively worsening.

• Peptic ulcer disease – recurrent or multiple ulcers in the stomach and duodenum, often larger than typical ulcers and resistant to standard therapy.
• Abdominal pain – usually epigastric, may be burning or cramping; often worsens on an empty stomach.
• Diarrhea – watery, sometimes greasy, caused by acid‑induced injury to the intestinal mucosa and bile salt inactivation.
• Steatorrhea (fatty stools) – malabsorption of fat due to acid‑mediated pancreatic enzyme inactivation.
• Weight loss – secondary to malabsorption, chronic diarrhea, and reduced appetite.
• Nausea & vomiting – can be triggered by ulcer pain or gastric outlet obstruction.
• Gastroesophageal reflux disease (GERD) – acid reflux symptoms may be more severe.
• Gastric bleeding – melena (black tarry stools) or hematemesis (vomiting blood) when ulcers erode blood vessels.
• Esophageal strictures – from chronic acid exposure, causing dysphagia (difficulty swallowing).
• Fever or chills – may indicate an ulcer complication such as perforation or infection.

Because the gastrinoma can be small and located deep within the pancreas or duodenum, many patients experience only vague abdominal discomfort for years before a definitive diagnosis is made.

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑producing neuroendocrine tumors. In the sporadic form, these tumors arise de novo, without an identifiable inherited mutation. The exact molecular triggers remain under investigation, but several pathways have been implicated:

• Somatic mutations in the MEN1 gene (found in up to 30 % of sporadic gastrinomas).
• Loss of heterozygosity at chromosome 11q13.
• Alterations in the KRAS and TP53 genes have also been observed in a minority of cases.

Risk factors

• Age – incidence rises after age 40.
• Male sex – modestly higher prevalence.
• Family history of gastrinomas or MEN‑1 – raises suspicion for the hereditary form; however, it does not necessarily increase risk for sporadic ZES.
• Chronic atrophic gastritis – long‑standing inflammation can raise gastrin levels, but does not cause true gastrinomas.

Diagnosis

Diagnosing sporadic ZES requires a combination of biochemical testing, imaging, and sometimes endoscopic evaluation. Because the clinical picture can mimic common ulcer disease, a high index of suspicion is essential.

1. Biochemical confirmation

• Fasting serum gastrin level – the most sensitive initial test. Values > 1,000 pg/mL (10 × upper limit of normal) are highly specific for ZES, especially when the gastric pH is < 2.<sup>4</sup>
• Secretin stimulation test – serum gastrin is measured before and after intravenous secretin (2 U/kg). In ZES, gastrin paradoxically rises ≥ 120 pg/mL after secretin, whereas in other conditions it falls.
• Gastric pH measurement – confirms hyperacidity (pH < 2) which supports gastrinoma diagnosis.

2. Imaging to locate the tumor

• Somatostatin receptor scintigraphy (SRS or Octreoscan) – detects tumors expressing somatostatin receptors; sensitivity ≈ 80 % for gastrinomas.
• 68Ga‑DOTATATE PET/CT – newer, higher‑resolution functional imaging; sensitivity > 90 % and now considered first‑line for tumor localization.<sup>5</sup>
• Multiphasic contrast‑enhanced CT or MRI – useful for anatomical detail, especially for hepatic metastases.
• EUS (Endoscopic Ultrasound) – highly sensitive for small (< 1 cm) duodenal or pancreatic gastrinomas.

3. Endoscopic evaluation

Upper endoscopy (EGD) is performed to assess ulcer burden, obtain biopsies (to exclude malignancy or H. pylori), and sometimes to directly visualize a submucosal duodenal tumor.

4. Staging

Once the primary tumor is identified, staging includes assessment for regional lymph node involvement and distant metastasis (commonly to the liver). The American Joint Committee on Cancer (AJCC) TNM system for pancreatic neuroendocrine tumors is applied.

Treatment Options

Management of sporadic ZES aims to control gastric acid hypersecretion, eradicate the tumor when possible, and monitor for recurrence.

Acid‑suppression therapy (first line)

• High‑dose proton pump inhibitors (PPIs) – e.g., omeprazole 60 mg daily or esomeprazole 40 mg twice daily. PPIs normalize gastric pH in > 90 % of patients.<sup>6</sup>
• Dosage is titrated based on symptom control and fasting gastrin levels. Long‑term PPI use is generally safe, but periodic monitoring of vitamin B12, magnesium, and bone density is advised.

Surgical treatment

Curative surgery is the goal when the tumor is localized and resectable.

• Enucleation – removal of the gastrinoma without surrounding pancreatic tissue; preferred for small (< 2 cm) tumors without invasion.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger pancreatic head tumors or when multiple duodenal lesions are present.
• Distal pancreatectomy – for tumors located in the body or tail of the pancreas.
• Complete surgical resection yields 5‑year disease‑free survival rates of 60–80 % for sporadic cases without metastasis.<sup>7</sup>

Medical therapy for unresectable or metastatic disease

• Somatostatin analogs (octreotide or lanreotide) – bind to somatostatin receptors, reducing gastrin secretion and tumor growth. Effective in ~50 % of patients with symptom control.<sup>8</sup>
• Targeted therapies – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) approved for pancreatic neuroendocrine tumors; can stabilize disease progression.
• Chemotherapy – streptozocin‑based regimens are reserved for high‑grade or rapidly progressive disease.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers targeted radiation; shows tumor shrinkage in 30–40 % of treated patients.

Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce post‑prandial acid spikes.
• Avoidance of NSAIDs, alcohol, and smoking – all exacerbate ulcer formation.
• Supplementation with calcium, vitamin D, and B12 if long‑term PPI therapy is used.

Living with Zollinger‑Ellison Syndrome (Sporadic)

Adapting to life with ZES involves more than medication; daily habits and monitoring are key.

Medication adherence

• Take PPIs exactly as prescribed—often 30 minutes before a meal.
• Carry a rescue antacid (e.g., calcium carbonate) for breakthrough symptoms.
• Set reminders for follow‑up labs (fasting gastrin, B12, magnesium) every 6–12 months.

Nutrition tips

• Prefer low‑acid foods (bananas, oatmeal, boiled vegetables).
• Limit citrus fruits, tomatoes, coffee, and carbonated drinks.
• Consume adequate protein to offset malabsorption; consider a medium‑chain triglyceride (MCT) oil supplement if fat malabsorption persists.

Regular monitoring

• Annual upper endoscopy if ulcers recur or if there is suspicion of malignant transformation.
• Imaging (CT/MRI or 68Ga‑DOTATATE PET) every 1–2 years for patients with known metastatic disease.
• Report new abdominal pain, vomiting, or changes in bowel habits promptly.

Psychosocial support

Living with a chronic rare disease can be stressful. Seek support groups (e.g., PNI's Neuroendocrine Tumor Patient Associations) and consider counseling to manage anxiety or depression.

Prevention

Because sporadic ZES arises from somatic mutations, there is no proven way to prevent its onset. However, some measures may lower overall gastrointestinal risk and improve outcomes:

• Maintain a healthy weight and avoid tobacco—both reduce the risk of neuroendocrine tumor development.
• Limit exposure to known pancreatic carcinogens (e.g., chronic heavy alcohol use, certain pesticides).
• Prompt treatment of H. pylori infection and avoidance of chronic NSAID use can prevent secondary ulcer disease that might mask ZES.

Complications

If left untreated or poorly controlled, ZES can lead to serious health issues:

• Perforated peptic ulcer – abdominal emergency with peritonitis.
• Bleeding ulcers – may require endoscopic hemostasis, transfusion, or surgery.
• Gastric outlet obstruction – due to ulcer scarring, leading to persistent vomiting.
• Metastatic disease – ~25 % of sporadic gastrinomas metastasize, most commonly to the liver and regional lymph nodes.
• Malnutrition and osteoporosis – chronic acid loss and long‑term PPI therapy can impair nutrient absorption.
• Neuroendocrine tumor transformation – rare, but high‑grade (poorly differentiated) tumors have a poorer prognosis.

When to Seek Emergency Care

---

Sources:

1. Boudreaux et al., 2015. Management of Zollinger‑Ellison syndrome.
2. Mayo Clinic – Zollinger‑Ellison syndrome.
3. J. Clin. Endocrinol. Metab., 2005 – Epidemiology of gastrinomas.
4. CDC – Rare Disease Information.
5. Fani et al., 2019 – 68Ga‑DOTATATE PET/CT in neuroendocrine tumors.
6. Cleveland Clinic – Treatment overview.
7. Sosa et al., 2016 – Surgical outcomes for sporadic gastrinomas.
8. Lang et al., 2016 – Somatostatin analogs in ZES.

```